Skip to main content
Fig. 3 | Stem Cell Research & Therapy

Fig. 3

From: Healthy, mtDNA-mutationĀ free mesoangioblasts from mtDNA patients qualify for autologous therapy

Fig. 3

Myogenic potency of mesoangioblasts from mtDNA carriers. The myogenic potential was quantified following 10ā€‰days of differentiation in 2% horse serum containing medium and quantification of the myogenic fusion index, namely the number of nuclei (DAPI) in myosin-positive (MF20) muscle fibers per total number of nuclei per field. a Example image of 10ā€‰days differentiated MABs following MF20 immunostaining of myotubes (green) and DAPI nuclear stain (blue). b Interaction between age at biopsy and the mesoangioblast mtDNA mutation load (irrespective of type of mtDNA mutation) on the spontaneous myogenic potential of mesoangioblasts, using the best linear regression model obtained and described by E(Myogenic fusion index)ā€‰=ā€‰0.146ā€‰āˆ’ā€‰0.00155ā€‰Ć—ā€‰ageā€‰āˆ’ā€‰0.0394ā€‰Ć—ā€‰ln(MABs)ā€‰+ā€‰0.00056ā€‰Ć—ā€‰ageā€‰Ć—ā€‰ln(MABs)

Back to article page